Unlabelled: Preclinical Research & Development Background: Samidorphan, a μ-opioid receptor antagonist, is in clinical development for central nervous system related diseases. The discriminative stimulus effects of samidorphan were assessed in rats trained to discriminate the effects of a known morphinan of abuse, morphine, from that of saline.
Methods: Escalating doses of samidorphan were substituted for morphine and rats were allowed to respond on two levers for food reward. Doses of samidorphan were chosen based on other pharmacodynamic assays in which samidorphan blocked the effects of morphine (such as blocking analgesia in a hot plate test; data not shown). In addition, a pharmacokinetic study was conducted to determine if these doses would reflect predicted exposure levels that translate to human equivalent doses.
Results: Rats discriminating morphine from vehicle responded predominantly on the vehicle lever after receiving samidorphan. In addition, samidorphan was rapidly absorbed, and plasma concentrations of the doses tested in this study bracket therapeutically relevant concentrations.
Conclusions: In summary, samidorphan produced saline-like behavioral responses over a wide dose range.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ddr.21437 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long-Term Safety, Tolerability, and Durability of Treatment Effect of Olanzapine and Samidorphan: Results of a 4-Year Open-Label Study.
J Clin Psychiatry
December 2024
Department of Psychiatry, Zucker Hillside Hospital, Glen Oaks, New York.
Article Synopsis
- - The study evaluated the long-term safety, tolerability, and effect of olanzapine/samidorphan (OLZ/SAM) in patients with schizophrenia, schizophreniform disorder, or bipolar I disorder for up to 4 years, following the ENLIGHTEN clinical program.
- - Out of 524 enrolled patients, the majority had schizophrenia, and common adverse effects included weight gain, headache, and anxiety, with minimal changes in metabolic parameters over the treatment duration.
- - The treatment showed stable scores on the Clinical Global Impressions-Severity scale, indicating maintained symptom control and a long-term safety profile consistent with previous studies.
Inhibitory effects of the selective μ-opioid receptor antagonist UD-030 on methamphetamine-induced conditioned place preference.
Neuropsychopharmacol Rep
March 2025
Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Although methamphetamine (METH) and other addictive substance use disorders are a major social problem worldwide, appropriate pharmacotherapies have not yet been discovered. Subtype-nonselective opioid receptor antagonists, such as naltrexone (NTX), have been reported to suppress METH addiction, but unclear are the opioid receptor subtypes that are involved in this beneficial effect. To clarify the role of μ-opioid receptors (MOPs), we examined effects of the novel nonpeptidic MOP-selective antagonist UD-030 on the acquisition and expression of METH-induced conditioned place preference (CPP) using behavioral tests in C57BL/6J mice.
View Article and Find Full Text PDFReal-World Effectiveness, Economic, and Humanistic Outcomes of Selected Oral Antipsychotics in Patients with Schizophrenia: A Systematic Review Evaluating Global Evidence.
Clinicoecon Outcomes Res
September 2024
Global Value & Access, Cerevel Therapeutics, Cambridge, MA, USA.
Background: Schizophrenia is a complex, chronic mental health disorder that confers a substantial disease burden globally. Oral antipsychotic treatments (OATs) are the mainstay for treating early and advanced stages of schizophrenia. Our systematic review aimed to synthesize literature describing real-world effectiveness, economic, and humanistic outcomes of OATs (asenapine, brexpiprazole, cariprazine, iloperidone, lumateperone, lurasidone, olanzapine/samidorphan, paliperidone, and quetiapine) for successful management of the disease.
View Article and Find Full Text PDFTreating Schizophrenia and Bipolar I Disorder in the Real-World Setting: Effectiveness and Safety of Olanzapine/Samidorphan Combination.
Prim Care Companion CNS Disord
April 2024
Department of Psychiatry, Weill Cornell Medical College, New York, New York.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!